RxDoctor Payments Data

J Mendius, MD

Neurology · Santa Rosa, CANPI 1295765881

Payments from drug & device makers

$2,822in general payments, 2019–2025

Across 13 payments — averaging $217.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • Boston Scientific$162
  • SK Life Science, Inc.$118
  • Greenwich Biosciences, Inc.$49
  • AstraZeneca$34
  • AbbVie$25
  • plus $15 from 1 others

What the payments were for

  • Speaking & faculty fees$2,26680%
  • Travel & lodging$512%
  • Food & beverage$49017%
  • Education$151%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi5$2,419
Boston Scientific2$162
SK Life Science, Inc.1$118
Greenwich Biosciences, Inc.1$49
AstraZeneca1$34
AbbVie(2 entities)2$25
UCB, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,822 in reported general payments places this provider in the 55th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$320,271
Medicare patients
721
Services billed
26,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$83,572
Aimovig AutoinjectorErenumab-Aooe59$60,845
Nurtec OdtRimegepant Sulfate29$48,719
Teriflunomide18$41,274
Emgality PenGalcanezumab-Gnlm42$40,958
UbrelvyUbrogepant21$21,418
Zolmitriptan34$16,247
Levetiracetam268$12,453
Rivastigmine21$8,699
Carbidopa-LevodopaCarbidopa/Levodopa176$6,181
Donepezil Hcl448$6,181
MyrbetriqMirabegron12$5,726
Carbamazepine52$5,546
Pregabalin90$5,314
Ropinirole Hcl147$4,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$25$21,41821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,996 neurology providers in California.

Other neurology in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →